289 related articles for article (PubMed ID: 31519161)
1. Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures.
Karakostis K; Fåhraeus R
BMC Cancer; 2019 Sep; 19(1):915. PubMed ID: 31519161
[TBL] [Abstract][Full Text] [Related]
2. p53 mRNA and p53 Protein Structures Have Evolved Independently to Interact with MDM2.
Karakostis K; Ponnuswamy A; Fusée LT; Bailly X; Laguerre L; Worall E; Vojtesek B; Nylander K; Fåhraeus R
Mol Biol Evol; 2016 May; 33(5):1280-92. PubMed ID: 26823446
[TBL] [Abstract][Full Text] [Related]
3. P53 mRNA controls p53 activity by managing Mdm2 functions.
Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation.
Tang J; Agrawal T; Cheng Q; Qu L; Brewer MD; Chen J; Yang X
PLoS One; 2013; 8(2):e55813. PubMed ID: 23405218
[TBL] [Abstract][Full Text] [Related]
5. A single synonymous mutation determines the phosphorylation and stability of the nascent protein.
Karakostis K; Vadivel Gnanasundram S; López I; Thermou A; Wang L; Nylander K; Olivares-Illana V; Fåhraeus R
J Mol Cell Biol; 2019 Mar; 11(3):187-199. PubMed ID: 30252118
[TBL] [Abstract][Full Text] [Related]
6. The p53 mRNA-Mdm2 interaction.
Naski N; Gajjar M; Bourougaa K; Malbert-Colas L; Fåhraeus R; Candeias MM
Cell Cycle; 2009 Jan; 8(1):31-4. PubMed ID: 19106616
[TBL] [Abstract][Full Text] [Related]
7. MDM2's dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities.
Gnanasundram SV; Malbert-Colas L; Chen S; Fusée L; Daskalogianni C; Muller P; Salomao N; Fåhraeus R
Nucleic Acids Res; 2020 Jul; 48(12):6775-6787. PubMed ID: 32453417
[TBL] [Abstract][Full Text] [Related]
8. p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress.
López I; Tournillon AS; Nylander K; Fåhraeus R
Cell Cycle; 2015; 14(21):3373-8. PubMed ID: 26397130
[TBL] [Abstract][Full Text] [Related]
9. Autoactivation of the MDM2 E3 ligase by intramolecular interaction.
Cheng Q; Song T; Chen L; Chen J
Mol Cell Biol; 2014 Aug; 34(15):2800-10. PubMed ID: 24842904
[TBL] [Abstract][Full Text] [Related]
10. HDMX folds the nascent p53 mRNA following activation by the ATM kinase.
Malbert-Colas L; Ponnuswamy A; Olivares-Illana V; Tournillon AS; Naski N; Fåhraeus R
Mol Cell; 2014 May; 54(3):500-11. PubMed ID: 24813712
[TBL] [Abstract][Full Text] [Related]
11. The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway.
Karakostis K; Malbert-Colas L; Thermou A; Vojtesek B; Fåhraeus R
Mol Cancer; 2024 Jan; 23(1):21. PubMed ID: 38263180
[TBL] [Abstract][Full Text] [Related]
12. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage.
Gajjar M; Candeias MM; Malbert-Colas L; Mazars A; Fujita J; Olivares-Illana V; Fåhraeus R
Cancer Cell; 2012 Jan; 21(1):25-35. PubMed ID: 22264786
[TBL] [Abstract][Full Text] [Related]
13. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
14. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
15. The regulation of MDM2 oncogene and its impact on human cancers.
Zhao Y; Yu H; Hu W
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
[TBL] [Abstract][Full Text] [Related]
16. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
17. The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer.
Padariya M; Jooste ML; Hupp T; Fåhraeus R; Vojtesek B; Vollrath F; Kalathiya U; Karakostis K
Mol Biol Evol; 2022 Jul; 39(7):. PubMed ID: 35792674
[TBL] [Abstract][Full Text] [Related]
18. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
19. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
20. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.
Galbán S; Martindale JL; Mazan-Mamczarz K; López de Silanes I; Fan J; Wang W; Decker J; Gorospe M
Mol Cell Biol; 2003 Oct; 23(20):7083-95. PubMed ID: 14517280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
